Heterozygote Advantage of the Type II Deiodinase Thr92Ala Polymorphism on Intrahospital Mortality of COVID-19.

ABSTRACT:

Context

The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and pulmonary fibrosis.

Objective

Our objectives were to evaluate were cumulative mortality during admission according to Thr92Ala-DIO2 polymorphism.

Methods

Here we conducted an observational, longitudinal, and prospective cohort study to investigate a possible association between the Thr92Ala-DIO2 polymorphism and intrahospital mortality from COVID-19 in adult patients admitted between June and August 2020. Blood biochemistry, thyroid function tests, length of stay, comorbidities, complications, and severity scores were also studied according to Thr92Ala-DIO2 polymorphism.

Results

In total, 220 consecutive patients (median age 62; 48-74

SUBMITTER: de Lima Beltrao FE 

PROVIDER: S-EPMC8903419 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature